186 related articles for article (PubMed ID: 19665217)
1. High-risk HPV DNA detected in less than 2% of over 25,000 cytology negative imaged liquid-based Pap test samples from women 30 and older.
Bansal M; Austin RM; Zhao C
Gynecol Oncol; 2009 Nov; 115(2):257-61. PubMed ID: 19665217
[TBL] [Abstract][Full Text] [Related]
2. Very low human Papillomavirus DNA prevalence in mature women with negative computer-imaged liquid-based Pap tests.
Zhao C; Elishaev E; Yuan KH; Yu J; Austin RM
Cancer; 2007 Oct; 111(5):292-7. PubMed ID: 17879368
[TBL] [Abstract][Full Text] [Related]
3. Age-specific detection of high risk HPV DNA in cytologically normal, computer-imaged ThinPrep Pap samples.
Cibas ES; Hong X; Crum CP; Feldman S
Gynecol Oncol; 2007 Mar; 104(3):702-6. PubMed ID: 17150245
[TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus DNA detection in ThinPrep Pap test vials is independent of cytologic sampling of the transformation zone.
Zhao C; Austin RM
Gynecol Oncol; 2007 Nov; 107(2):231-5. PubMed ID: 17854873
[TBL] [Abstract][Full Text] [Related]
5. Adjunctive high-risk human papillomavirus DNA testing is a useful option for disease risk assessment in patients with negative Papanicolaou tests without an endocervical/transformation zone sample.
Zhao C; Austin RM
Cancer; 2008 Aug; 114(4):242-8. PubMed ID: 18484643
[TBL] [Abstract][Full Text] [Related]
6. Reflex human papillomavirus DNA testing on residual liquid-based (TPPT) cervical samples: focus on age-stratified clinical performance.
Sarode VR; Werner C; Gander R; Foster B; Fulmer A; Saboorian MH; Ashfaq R
Cancer; 2003 Jun; 99(3):149-55. PubMed ID: 12811855
[TBL] [Abstract][Full Text] [Related]
7. The prevalence of HR-HPV DNA in ASC-US Pap smears: A military population study.
Stany MP; Bidus MA; Reed EJ; Kaplan KJ; McHale MT; Rose GS; Elkas JC
Gynecol Oncol; 2006 Apr; 101(1):82-5. PubMed ID: 16290002
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of high-risk human papillomavirus type 16/18 infection among women with normal cytology: risk factor analysis and implications for screening and prophylaxis.
Gupta S; Sodhani P; Sharma A; Sharma JK; Halder K; Charchra KL; Sardana S; Singh V; Sehgal A; Das BC
Cytopathology; 2009 Aug; 20(4):249-55. PubMed ID: 19018810
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and type distribution of high-risk human papillomavirus infection in women undergoing voluntary cervical cancer screening in Italy.
Agarossi A; Ferrazzi E; Parazzini F; Perno CF; Ghisoni L
J Med Virol; 2009 Mar; 81(3):529-35. PubMed ID: 19152401
[TBL] [Abstract][Full Text] [Related]
10. Molecular testing of human papillomavirus in cervical specimens.
Gazzaz FB
Saudi Med J; 2007 Dec; 28(12):1810-8. PubMed ID: 18060207
[TBL] [Abstract][Full Text] [Related]
11. Epidemiologic correlates of cervical human papillomavirus prevalence in women with abnormal Pap smear tests: a Taiwan Cooperative Oncology Group (TCOG) study.
Sun CA; Hsiung CA; Lai CH; Chen CA; Chou CY; Ho CM; Twu NF; Feng WL; Chuang MH; Hsieh CY; Chu TY
J Med Virol; 2005 Oct; 77(2):273-81. PubMed ID: 16121376
[TBL] [Abstract][Full Text] [Related]
12. Detection and genotyping of cervical HPV with simultaneous cervical cytology in Turkish women: a hospital-based study.
Yuce K; Pinar A; Salman MC; Alp A; Sayal B; Dogan S; Hascelik G
Arch Gynecol Obstet; 2012 Jul; 286(1):203-8. PubMed ID: 22395863
[TBL] [Abstract][Full Text] [Related]
13. The evaluation of human papillomavirus genotyping in cervical liquid-based cytology specimens; using the Roche Linear Array HPV genotyping assay.
Jamison J; Wilson RT; Carson J
Cytopathology; 2009 Aug; 20(4):242-8. PubMed ID: 19291176
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of adding human papilloma virus testing to a managed care cervical cancer screening program.
Lonky NM; Hunter MI; Sadeghi M; Edwards G; Bajamundi K; Monk BJ
J Low Genit Tract Dis; 2007 Oct; 11(4):258-64. PubMed ID: 17917570
[TBL] [Abstract][Full Text] [Related]
15. Improved endocervical sampling and HPV viral load detection by Cervex-Brush Combi.
Depuydt CE; Benoy IH; Bailleul EJ; Vandepitte J; Vereecken AJ; Bogers JJ
Cytopathology; 2006 Dec; 17(6):374-81. PubMed ID: 17168921
[TBL] [Abstract][Full Text] [Related]
16. Combined Pap and HPV testing in primary screening for cervical abnormalities: should HPV detection be delayed until age 35?
Baay MF; Tjalma WA; Lambrechts HA; Pattyn GG; Lardon F; Weyler J; Van Royen P; Van Marck EA; Vermorken JB
Eur J Cancer; 2005 Nov; 41(17):2704-8. PubMed ID: 16242316
[TBL] [Abstract][Full Text] [Related]
17. Assessing the role of education in women's knowledge and acceptance of adjunct high-risk human Papillomavirus testing for cervical cancer screening.
Papa D; Moore Simas TA; Reynolds M; Melnitsky H
J Low Genit Tract Dis; 2009 Apr; 13(2):66-71. PubMed ID: 19387125
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and risk factors of human papillomavirus infection in asymptomatic women in a Venezuelan urban area.
Núñez-Troconis J; Delgado M; González J; Mindiola R; Velásquez J; Conde B; Whitby D; Munroe DJ
Invest Clin; 2009 Jun; 50(2):203-12. PubMed ID: 19662815
[TBL] [Abstract][Full Text] [Related]
19. The prevalence of different HPV types in Turkish women with a normal Pap smear.
Demir ET; Ceyhan M; Simsek M; Gunduz T; Arlier S; Aytac R; Aycan AE; Gurbuz V
J Med Virol; 2012 Aug; 84(8):1242-7. PubMed ID: 22711352
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening.
Bidus MA; Maxwell GL; Kulasingam S; Rose GS; Elkas JC; Chernofsky M; Myers ER
Obstet Gynecol; 2006 May; 107(5):997-1005. PubMed ID: 16648402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
